George Blanck, PhD

George Blanck, PhD



    • Immunology

Education & Training

    • Columbia University, PhD - Cell and Molecular Biology
    • Universite de Paris VI, Fellow - INSERM
    • Harvard University, Cambridge, Massachusetts, Fellow - Multiple Sclerosis
    • Columbia University, New York, NY, Research Fellow - Biological Sciences

  • Callahan BM, Patel JS, Fawcett TJ, Blanck G. Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir. Int J Cancer. 2018 Mar;142(5):988-998. Pubmedid: 29047110.
  • Sikaria D, Tu YN, Fisler DA, Mauro JA, Blanck G. Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. J Cancer Res Clin Oncol. 2018 Jan. Pubmedid: 29305708.
  • Uversky VN, Tu YN, Nwogu O, Butler SN, Ramsamooj M, Blanck G. High-level intrinsic disorder explains the universality of CLIP binding to diverse MHC class II variants. Cell Mol Immunol. 2018 Jan;15(1):76-78. Pubmedid: 28757614.
  • Mauro JA, Yavorski JM, Blanck G. Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. Gene. 2017 May;614:37-48. Pubmedid: 28257835.
  • Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunol Immun. 2017 Mar;66(3):403-410. Pubmedid: 27995306.
  • Yavorski JM, Stoll RJ, Samy MD, Mauro JA, Blanck G. Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome. Curr Genomics. 2017 Jun;18(3):287-297. Pubmedid: 28659724. Pmcid: PMC5476947.
  • Tu YN, Tong WL, Samy MD, Yavorski JM, Kim M, Blanck G. Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-α/β V(D)J recombinations correlates with PD-1 expression. Int J Cancer. 2017 Jun;140(11):2568-2576. Pubmedid: 28256716.
  • Stoll RJ, Thompson GR, Samy MD, Blanck G. De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions. Biomed Rep. 2017 Feb;6(2):211-216. Pubmedid: 28357075. Pmcid: PMC5351269.
  • Yavorski JM, Blanck G. MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Mol Clin Oncol. 2017 Dec;7(6):1119-1121. Pubmedid: 29285385. Pmcid: PMC5740846.
  • Clark NM, Garcia Galindo CA, Patel VK, Parry ML, Stoll RJ, Yavorski JM, Pinkason EP, Johnson EM, Walker CM, Johnson J, Sexton WJ, Coppola D, Blanck G. The human, F-actin-based cytoskeleton as a mutagen sensor. Cancer Cell Int. 2017 Dec;17:121. Pubmedid: 29255378. Pmcid: PMC5727871.
  • Tu YN, Tong WL, Fawcett TJ, Blanck G. Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. Lab Invest. 2017 Dec;97(12):1516-1520. Pubmedid: 28805806.
  • Segarra DT, Yavorski JM, Blanck G. Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer. Biomed Rep. 2017 Aug;7(2):163-168. Pubmedid: 28804630. Pmcid: PMC5526129.
  • Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother. 2017 03;13(3):501-506. Pubmedid: 28085544. Pmcid: PMC5360147.
  • Sait S, Fawcett T, Blanck G. Overlap of the cancer genome atlas and the immune epitope database. Oncol Lett. 2016 Oct;12(4):2982-2984. Pubmedid: 27703532. Pmcid: PMC5038905.
  • Samy MD, Yavorski JM, Mauro JA, Blanck G. Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach. Cell Cycle. 2016 Jun;15(12):1572-1578. Pubmedid: 27074591. Pmcid: PMC4934054.
  • Butler SN, Blanck G. Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA. Cell Tissue Res. 2016 Feb;363(2):491-496. Pubmedid: 26293619.
  • Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of Productively Rearranged TcR-α V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. Cancer Inform. 2016 Feb;15:23-28. Pubmedid: 26966347. Pmcid: PMC4768948.
  • Yavorski JM, Blanck G. Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas. Physiol Rep. 2016 Dec;4(24). Pubmedid: 28039401. Pmcid: PMC5210378.
  • Parry ML, Blanck G. Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?. Hum Vaccin Immunother. 2016 Dec;12(1):120-123. Pubmedid: 26225584. Pmcid: PMC4962751.
  • Yavorski JM, Blanck G. TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma. Cell Cycle. 2016 Aug;15(16):2157-2163. Pubmedid: 27355872. Pmcid: PMC4993568.
  • Blazekovic F, Odukoya D, Butler SN, Mauro JA, Ramsamooj M, Puleo E, Szekeres K, Dana D, Kumar S, Ragupathi G, Blanck G. HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. Hum Vaccin Immunother. 2016 03;12(3):593-598. Pubmedid: 26453454. Pmcid: PMC4964726.
  • Blanck G. The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos. Hum Vaccin Immunother. 2015 Mar;10(3):700-702. Pubmedid: 24346686. Pmcid: PMC4130267.
  • Frangione ML, Lockhart JH, Morton DT, Pava LM, Blanck G. Anticipating designer drug-resistant cancer cells. Drug Discov Today. 2015 Jul;20(7):790-793. Pubmedid: 25697478.
  • Lloyd MC, Szekeres K, Brown JS, Blanck G. Class II transactivator expression in melanoma cells facilitates T-cell engulfment. Anticancer Res. 2015 Jan;35(1):25-29. Pubmedid: 25550531.
  • Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: a connection to cancerous, spherical cells?. Cancer Lett. 2015 Jan;356(2 Pt B):479-482. Pubmedid: 25451318.
  • Ford SA, Blanck G. Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies. Biochim Biophys Acta. 2015 Jan;1855(1):18-23. Pubmedid: 25450826.
  • Mauro JA, Butler S, Ramsamooj M, Blanck G. Copy number loss or silencing of apoptosis-effector genes in cancer. Gene. 2015 Jan;554(1):50-57. Pubmedid: 25307873.
  • Garcia M, Mauro JA, Ramsamooj M, Blanck G. Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. Cell Cycle. 2015 Aug;14(15):2494-2500. Pubmedid: 25945879. Pmcid: PMC4615035.
  • Blanck G. Letter to the Editor: Giant proteins and cancer chemotherapy cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Aug;309(4):H718. Pubmedid: 26276978.
  • Blanck G. The Rise of the Biomedical Sciences Master's Program at U.S. Medical Colleges. Teach Learn Med. 2014 Oct;26(4):409-411. Pubmedid: 25318038.
  • Mauro JA, Blanck G. Functionally distinct gene classes as bigger or smaller transcription factor traps: a possible stochastic component to sequential gene expression programs in cancer. Gene. 2014 Feb;536(2):398-406. Pubmedid: 24291030.
  • Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment. Exp Mol Pathol. 2014 Dec;97(3):585-589. Pubmedid: 25236570. Pmcid: PMC4742287.
  • Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G. Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. Gene. 2013 Jan;512(2):403-407. Pubmedid: 23041127.
  • Cronin K, Escobar H, Szekeres K, Reyes-Vargas E, Rockwood AL, Lloyd MC, Delgado JC, Blanck G. Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vaccin Immunother. 2013 Apr;9(4):784-789. Pubmedid: 23328677. Pmcid: PMC3903896.
  • Pava LM, Morton DT, Chen R, Blanck G. Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes Are Evolutionarily Conserved. Cancer Genomics Proteomics. 2012 Nov;9(6):389-395. Pubmedid: 23162078.
  • Long K, Abuelenen T, Pava L, Bastille M, Blanck G. Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes. Genes Cancer. 2011 Oct;2(10):927-931. Pubmedid: 22701759. Pmcid: PMC3374629.
  • Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol. 2009 Sep;135(9):1287-1291. Pubmedid: 19288270.
  • Niesen MI, Osborne AR, Lagor WR, Zhang H, Kazemfar K, Ness GC, Blanck G. Technological advances in the study of HLA-DRA promoter regulation: Extending the functions of CIITA, Oct-1, Rb, and RFX. Acta Biochim Biophys Sin (Shanghai). 2009 Mar;41(3):198-205. Pubmedid: 19280058.
  • Niesen MI, Blanck G. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull. 2009 Mar;32(3):480-482. Pubmedid: 19252299.
  • Narsing S, Jelsovsky Z, Mbah A, Blanck G. Genes that contribute to cancer fusion genes are large and evolutionarily conserved. Cancer Genet Cytogenet. 2009 Jun;191(2):78-84. Pubmedid: 19446742.
  • Kazemfar K, Chen R, Nicholson K, Coppola D, Zhou JM, Chen X, Wei S, Blanck G. Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunol Lett. 2009 Jan;122(1):25-29. Pubmedid: 19056425.
  • Xu L, Niesen MI, Blanck G. Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Mol Immunol. 2009 Feb;46(4):569-575. Pubmedid: 18952290.
  • Palubin K, Goodwin B, Niesen M, Le E, Osborne A, Blanck G. A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice. Anticancer Res. 2006 May;26(3A):1733-1738. Pubmedid: 16827100.
  • Osborne AR, Zhang H, Blanck G. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line. Mol Immunol. 2006 Feb;43(6):710-716. Pubmedid: 16360016.
  • Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, Boss JM, Blanck G. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. J Biol Chem. 2005 Nov;280(47):38914-38922. Pubmedid: 16166088.
  • Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem. 2004 Jul;279(28):28911-28919. Pubmedid: 15105429.
  • Blanck G. Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunol Immunother. 2004;53(1):1-16. Pubmedid: 13680191.
  • Eason D, LeBron C, Coppola D, Moscinski L, Livingston S, Sutton E, Blanck G. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene. 2003 Sep;22(40):6166-6176. Pubmedid: 13679855.
  • Xi H, Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Mol Immunol. 2003;39:677-684. Pubmedid: 12493643.
  • Blanck G. Components of the IFN-gamma signaling pathway in tumorigenesis. Arch Immunol Ther Exp. 2002;50(3):151-158. Pubmedid: 12098930.
  • Eason D, Coppola D, Livingstone S, Blanck G, Shepherd A. Loss of MHC class II inducibility in hyperplastic tissue in Rb-defective mice. Cancer Lett. 2001 Oct;171(2):209-214. Pubmedid: 11520605.
  • Goodwin B, Xi H, Tejiram R, Eason D, Ghosh D, Wright K, Nagarajan U, Boss J, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 2001;12(6):327-335. Pubmedid: 11432807.
  • Eason D, Blanck G. High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. J Immunol. 2001;166(2):1041-1048. Pubmedid: 11145683.
  • Osborne A, Zhang H, Yang W, Seto E, Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol. 2001;21(19):6495-6506. Pubmedid: 11533238.
  • Xi H, Goodwin B, Shepherd A, Blanck G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene. 2001;20(31):4219-4227. Pubmedid: 11464288.
  • Zhang H, Wei S, Sun J, Coppola D, Zhong B, Wu G, Goodwin B, Sebti S, Djeu JY, Blanck G. Retinoblastoma protein activation of interleukin 8 expression inhibits tumor cell survival in nude mice. Cell Growth Differ. 2000 Dec;11(12):635-639. Pubmedid: 11149598.
  • Xi H, Blanck G. Interferon regulatory factor-2 point mutations in human pancreatic tumors. Int J Cancer. 2000;87(6):803-808. Pubmedid: 10956389.
  • Xi H, Eason D, Ghosh D, Dovhey S, Wright K, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 1999 Oct;18(43):5889-5903. Pubmedid: 10557076.
  • Eason D, Shepherd A, Blanck G. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochim Biophys Acta. 1999 Jul;1446(1-2):140-144. Pubmedid: 10395927.
  • Zhang H, Shephard AT, Eason DD, Wei S, Diaz JI, Djeu JY, Wu GD, Blanck G. Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Cell Growth Differ. 1999 Jul;10(7):457-465. Pubmedid: 10437913.
  • Lu Y, Tschickardt M, Schmidt B, Blanck G. IFN-gamma inducibility of CIITA is specifically lacking in human tumor lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol. 1997;75:325-332. Pubmedid: 9315472.
  • Osborne A, Tschickardt M, Blanck G. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res. 1997;25:5095-5102. Pubmedid: 9396821.
  • Lu Y, Boss J, Hu S, Xu H, Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. J Immunol. 1996;156:2495-2502. Pubmedid: 8786310.
  • Berry D, Lu Y, Schmidt B, Fallon P, O'Connell C, Hu S, Xu H, Blanck G. Retinoblastoma protein inhiibits IFN-(gamma) induced apoptosis. Oncogene. 1996;12:1809-1819. Pubmedid: 8622902.
  • Schmidt B, Carter S, Berry D, Blanck G. Vitamin D3 reduces the apoptotic effect of IFN-(gamma) but does not facilitate HLA class II inducibilitys in RB-defective cells. Cancer Lett. 1996;110:169-176. Pubmedid: 9018097.
  • Tschickardt M, Lu Y, Jacim M, Ussery G, Steimle B, Mach B, Blanck G. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class II transactivator CIITA in class II noninducible RB-defective tumor lines. Int J Cancer. 1995;62:461-465. Pubmedid: 7635572.
  • Fawcett TJ, Parry ML, Blanck G. A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. Cancer Genomics Proteomics. 12(6):283-290. Pubmedid: 26543077.